CAMELLIA-TIMI 61 was a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with CV disease and/or multiple CV risk factors. MAIN RESULTS:Cardiovascular Safety of Lorcaserin in Overweight or Obese PatientsN Engl J Med. 2018 Sep 20;379(12):1107-1117. PRESENTATIONS Primary Results (Bohula, ESC 2018)Metabolic Slides (Scirica, EASD 2018)Renal Outcomes (Bohula, AHA 2018)Predictive value of … Continue reading CAMELLIA-TIMI 61